Envestnet Asset Management
PGNX

Envestnet Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Envestnet Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,296
Closed -$27K – 2957
2018
Q2 		$27K Sell
3,296
-318
-9% -$2.43K ﹤0.01% 2360
2018
Q1 		$26K Buy
3,614
+1,299
+56% +$8.64K ﹤0.01% 2315
2017
Q4 		$14K Sell
2,315
-1,530
-40% -$9.29K ﹤0.01% 2579
2017
Q3 		$28K Buy
3,845
+185
+5% +$1.18K ﹤0.01% 2439
2017
Q2 		$25K Sell
3,660
-74
-2% -$546 ﹤0.01% 2554
2017
Q1 		$36K Sell
3,734
-8
-0.2% -$80 ﹤0.01% 2529
2016
Q4 		$32K Buy
+3,742
New +$27.7K ﹤0.01% 2563

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Envestnet Asset Management's PGNX Position: Q3 2018 in Review

Envestnet Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 3,296 shares — an estimated $27K sold.

Envestnet Asset Management first reported a position in PGNX in Q4 2016 and held it in 7 quarters. The position peaked at $36K in Q1 2017. 149 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

  • Envestnet Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Envestnet Asset Management sold 3,296 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $27K.
  • Envestnet Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 7 quarters.
  • Envestnet Asset Management's Progenics Pharmaceuticals Inc position peaked at $36K in Q1 2017.
  • 149 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Envestnet Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.